Mutations of K-ras have been found in 30-60% of colorectal carcinomas and are believed to be associated with tumor initiation, tumor progression and metastasis formation. Therefore, silencing of mutant K-ras expression has become an attractive therapeutic strategy for colorectal cancer treatment. The aim of our study was to investigate the effect of microRNA (miRNA) molecules directed against K-ras (miRNA-K-ras) on K-ras expression level and the growth of colorectal carcinoma cell line LoVo in vitro and in vivo. In addition, we evaluated electroporation as a gene delivery method for transfection of LoVo cells and tumors with plasmid DNA encoding miRNA-K-ras (pmiRNA-K-ras). Results of our study indicated that miRNAs targeting K-ras efficiently reduced K-ras expression and cell survival after in vitro electrotransfection of LoVo cells with pmiRNA-K-ras. In vivo, electroporation has proven to be a simple and efficient delivery method for local administration of pmiRNA-K-ras molecules into LoVo tumors. This therapy shows pronounced antitumor effectiveness and has no side effects. The obtained results demonstrate that electrogene therapy with miRNA-K-ras molecules can be potential therapeutic strategy for treatment of colorectal cancers harboring K-ras mutations.
Introduction
K-ras is a 21-kDa protein located at the inner plasma membrane and has an important role in transduction of extracellular signals from epidermal growth factor receptor to downstream effectors involved in cell division, apoptosis and differentiation of cells. 1 It is transiently activated as a response to growth factors, cytokines and hormones that stimulate cell surface receptors. Although the wild-type protein is inactivated after short time, mutated K-ras protein remains constitutively activated in the absence of any upstream stimulation of epidermal growth factor receptors. This leads to abnormal cell growth, proliferation and differentiation, and consequently to tumor initiation, tumor progression, angiogenesis and metastasis formation.
1,2 Mutations of K-ras have been found in 80-90% of pancreatic cancers, 3 30-60% of colorectal cancers, 4 ,5 20-30% of non-small cell lung cancers 6 and 5% of squamous cell carcinomas of the head and neck. 7 Therefore, K-ras oncogene represents an attractive target for cancer treatment.
Silencing of K-ras messenger RNA (mRNA) by RNA interference (RNAi) has been studied in vitro and in vivo, mostly on pancreatic adenocarcinoma cell lines. It was shown that properly designed small interfering RNA (siRNA) sequences efficiently inhibited the expression of mutated K-ras, whereas expression of wild-type (WT) K-ras remained unaffected. [8] [9] [10] [11] [12] The inhibition of K-ras expression by RNAi was reflected in reduced K-ras mRNA and proteins level, reduced proliferation and migration of cells, increased apoptosis, reduced angiogenic potential and decreased production of vascular endothelial cells. In the experiments, in vivo, on pancreatic tumors, delay in tumor growth was observed. 11, 13 Electroporation is a nonviral physical method for facilitated delivery of various molecules into cells, including genes. [14] [15] [16] Electrically assisted gene delivery, called electrotransfection, increased transfection efficiency of either reporter genes or therapeutic genes compared with injection of gene alone. 17, 18 To date several preclinical and clinical studies using electroporation (EP) and therapeutic genes for cancer treatment led to encouraging results demonstrating antitumor effectiveness. [19] [20] [21] [22] Owing to high mutation rate of K-ras also in colorectal cancer, silencing of K-ras in colorectal cancer is an attractive therapeutic approach. Therefore, the aim of our study was to identify the effective siRNA molecule against K-ras in human adenocarcinoma cell line LoVo by testing different siRNA sequences. On the basis of the most effective siRNA sequence, we designed plasmid DNA that encoded K-ras-specific miRNA. Our final aim was to investigate whether electrotransfection of LoVo cells with pmiRNA-K-ras can inhibit K-ras expression level and to determine its antitumor effect in vitro and on solid tumors in vivo.
Materials and methods

Colorectal tumor cell line
Human colorectal adenocarcinoma cell line LoVo (American Type Culture Collection, Rockville, MD) was cultured in F12 (HAM) medium (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum, 10 mM L-glutamine (Gibco BRL, Paisley, UK), 350 mg l À1 gentamicin (Krka, Novo mesto, Slovenia) and 1 ml l À1 crystacillin (Pliva d.d, Zagreb, Croatia) in a 5% CO 2 humidified incubator at 37 1C. Cell line LoVo was chosen on the basis of literature data indicating that LoVo cells harbor a K-ras point mutation at codon 13. [23] [24] [25] As a control cell line, HT29 (91072201 ECACC, Porton Down, UK) cell with WT K-ras were selected. 26 They were grown in Advanced Eagle's minimum essential medium (Gibco) supplemented with 2% fetal bovine serum (Gibco), 2 mM L-glutamine, 1 mM sodium pyruvate and 350 mg l À1 gentamicin and 1 ml l À1 crystacillin. 0 . The control scrambled sequences were, by manufacturer's assurance, designed in a way that had no homology to any known gene in human genome. The siRNA duplexes were obtained as ready-annealed, purified duplexes from Invitrogen and diluted in H 2 O to a concentration of 20 mM.
Construction of polymerase II miR RNAi expression plasmid
We constructed plasmid DNA that encode miRNA specific to K-ras (pmiRNA-K-ras) and plasmid DNA that encode control miRNA (pmiRNA-ctrl), which had no homology to any gene in genome. For this purpose, three different siRNAs were tested in vitro. Sequence of the most effective siRNA was chosen to design appropriate complementary DNA oligos that were annealed and cloned into pcDNATM6.2-GW/ ± EmGFP-miR plasmid vector obtained from Invitrogen. The complete sequence of plasmid and expressed pre-miRNA molecules are available on the Invitrogen website (www.invitrogen. com). Annealing of complementary DNA oligos, ligation of generated double-stranded DNA with pcDNATM6.2-GW/ ± EmGFP-miR plasmid vector and transformation of constructed plasmid DNA into competent Escherichia coli Top10 were performed using BLOCK-iT polymerase II miR RNAi Expression vector kit (Invitrogen), according to manufacturer's instructions. The presence and correct orientation of the K-ras double-stranded DNA insert as well as the sequence of the double-stranded DNA insert were confirmed by sequencing of pcDNATM6. 2-GW/miR expression clones using PCR amplified double-stranded DNA insert, EmGFP-miR forwardsequencing primer (5 0 -GGCATGGACGAGCTGTACA A-3 0 ), miRNA reverse-sequencing primer (5 0 -CTCTAGAT CAACCACTTTGT-3 0 ) and ABI PRISM Big Dye Terminator v1.1 Kit (Applied Biosystems, Warrington, UK). Samples were analyzed by sequenator ABI310 (Applied Biosystems, Waldbronn, Germany). Large quantities of plasmid DNA were prepared using EndoFree Plasmid Maxi Kit (Qiagen, Hilden, Germany) and diluted in water to a final concentration of 1 mg ml À1 .
In vitro lipofection Cells grown as monolayer were collected and a cell suspension of 2-4 Â 10 5 cells per ml was prepared in antibiotics-free medium. For lipofection of cells with siRNA molecules, siRNA duplex-Lipofectamine RNAiMax complex was prepared as follows: 5 ml of 20 mM siRNA was diluted in 2 ml Opti-MEM I medium (Invitrogen; Gibco) without serum to which 30 ml Lipofectamine RNAiMax (Invitrogen) was added. The mixture was then incubated for 10-20 min at room temperature. In each Petri dish with siRNA duplexLipofectamine RNAiMAX complexes, 8 ml of diluted cells was added. This gave a final RNA concentration of 10 nM. Cells were incubated at 37 1C in a 5% CO 2 humidified incubator for 48 h before collection of cells for RNA isolation.
In vitro electrotransfection
LoVo cells grown as monolayer were collected and a cell suspension of 2.5 Â 10 7 cells per ml was prepared in EP buffer (125 mM sucrose, 10 mM K 2 HPO 4 , 2.5 mM KH 2 PO 4 , 2 mM MgCl 2 Á 6 H 2 O). Dense cell suspension with concentration of 1 Â 10 6 cells and 10 mg of pmiRNA-K-ras or pmiRNA-ctrl in 50 ml of EP buffer were placed between two flat parallel stainless steel electrodes with a 2-mm gap connected to the GT-1 electroporator (University of Ljubljana, Faculty of Electrical Engineering, Ljubljana, Slovenia) and subjected to eight square-wave electric pulses with an amplitude per distance ratio 700 V cm À1 , 5 ms duration time and 1 Hz repetition frequency. After the exposure to electric pulses cells were incubated for 5 min at room temperature and then growth medium was added.
Clonogenic assay
After the specific treatment, cells (250-500) were plated on 6-cm Petri dishes with 4 ml medium and incubated in a 5% CO 2 humidified incubator at 37 1C. After 10-12 days, colonies were stained with crystal violet and counted. Colonies containing less than 50 cells were ignored. Plating efficiency and the surviving fraction were then calculated. The experiments were performed in triplicates and repeated three times.
RNA extraction and quantitative RT-PCR analysis Total RNA was extracted from cells the second day after lipofection or electrotransfection using TRIzol Plus RNA Purification Kit (Invitrogen) according to the manufacturers instructions. The RNA concentrations were quantified by spectrophotometer at 260 nm. A total of 1-2 mg of total RNA was reverse transcribed into complementary DNA using SuperScript VILO cDNA Synthesis Kit (Invitrogen), according to manufacturer's instructions. After reverse transcription, 2 ml of the undiluted or 10 Â diluted mixture was used as the template for the following quantitative RT-PCR using TaqMan Gene Expression Master mix (Applied Biosystems) and TaqMan Gene Expression Assay (Applied Biosystems). TaqMan Gene Expression Assay contained pair of primers and TaqMan MGB probe (ID Hs00364282_m1) to amplify the fragment of K-ras or TaqMan MGB probe (ID Hs99999901_s1) to amplify 18S mRNA, which was used as an internal control. A total of 50 cycles of PCR was performed as follows: activation of AmpliTaq Gold Enzyme (10 min at 95 1C), denaturation (15 s at 95 1C), annealing and extension (1 min 60 1C). The PCR products were analyzed using 7300 System SDS software (Applied Biosystems). The level of K-ras expression in each sample was normalized against the 18S mRNA.
Western blot analysis
Cells were seeded onto 10-cm Petri dishes after lipofection. At 3 days after treatment, cells were washed with ice-cold PBS and lysed in RIPA lysis buffer (Santa Cruz Biotechnology, Santa Cruz, CA) with freshly added protease inhibitors and phosphatase inhibitors (Santa Cruz Biotechnology). Cells were incubated on ice for 30 min and then homogenized by sonification for 15 s. Subsequently, whole-cell extracts were centrifuged at 10000 g and 4 1C, and protein concentrations were determined using Bio-Rad protein assay kit (Pierce, Rockford, IL). A total of 40 mg of proteins from each sample was separated on 10% SDS-PAGE and semi-dry transferred to a polyvinylidene fluoride membrane (Pierce) for 45 min at 0.08 A. The membranes were blocked with 5% low-fat dried milk (Pomurske mlekarne, Murska Sobota, Slovenia) in Tris-buffered saline (pH 7.4) containing 0.1% Tween-20 for 2 h at room temperature. The membrane was incubated with monoclonal primary antibody overnight at 4 1C, and then washed membranes were incubated with horseradish peroxide-conjugated goat anti-mouse secondary antibody for 45 min at room temperature. Mouse primary antibodies against K-ras (F234: sc-30, 1: 100, Santa Cruz Biotechnology) and b-actin (C4: sc-47778, 1:500, Santa Cruz Biotechnology) were used and horseradish peroxide-conjugated goat antimouse secondary antibody IgG 2a (sc-2061, 1:1000, Santa Cruz Biotechnology) or IgG (554002, 1:1000, BD Bioscience Pharmingen, San Diego, CA) were used. b-Actin was used as a control to demonstrate that identical amounts of protein were used for western blots. Protein bands were detected after incubation of the membrane with chemo-luminescent reagent (Santa Cruz Biotechnology) and 1-min exposure to film. Optical densities of proteins were determined by the Image J software system (National Institute of Health, Research Services Branch, Bethesda, MD).
Tumor models
Animal studies were carried out in accordance with the guidelines for animal experiments of the European Union directives and the permission from the Ministry of Agriculture, Forestry and Food of the Republic of Slovenia (permission no.: 323-02-632/2005/6). In the in vivo experiments, 6-8-week-old SCID-C.B-17/IcrHsdPrkdc scid female mice (Harlan, Udine, Italy) were used. Mice were maintained under specific pathogen-free conditions at a constant room temperature (21 1C) and a 12-h light/dark cycle. Food and water were provided ad libitum. Animals were subjected to an adaptation period of 7 days before experiments. For induction of subcutaneous tumors, suspension of 2 Â 10 6 LoVo cells, prepared from cell culture in vitro in 0.1 ml physiological solution, was injected into the right flank of mice. When tumors reached the volume of 40 mm 3 (in 10-14 days after subcutaneous injection of cells) animals were divided into experimental groups (10-12 animals per group) and subjected to specific experimental protocols as follows: control group: intratumoral injection of pmiRNA-K-ras (50 mg) using 23-gauge needle, intratumoral injection of control plasmid pmiRNA-ctrl (50 mg), EP, electrotransfection of tumors with pmiRNA-K-ras and electrotransfection of tumors with pmiRNA-ctrl. Electric pulses were delivered through two parallel stainless steel electrodes with 6-mm distance between them. Eight square-wave electric pulses were delivered in two sets of four pulses in perpendicular directions at a frequency of 1 Hz, amplitude over distance ratio 600 V cm À1 and 5-ms duration time. Electric pulses were generated by electroporator Jouan GHT 1287 (Jouan, St Herblain, France). Electrodes were placed percutaneously at opposite margins of the tumor. In electrotransfection protocol, electric pulses were applied 10 min after intratumoral injection of plasmid DNA. 27 Assessment of in vivo electrogene therapy using miRNA-K-ras Electrogene therapy of LoVo tumors with pmiRNA-K-ras was assessed by comparing the effects of electrotransfection with pmiRNA-K-ras to other treatment procedures. Quantitative RT-PCR: on day 6 after treatment, two tumors per group were excised and frozen in liquid nitrogen. Frozen tumors were homogenized in mortar with pestle and thereafter a total RNA was extracted from LoVo tumors using TRIzol Plus RNA Purification Kit (Invitrogen) according to the manufacturer's instructions. The quantitative RT-PCR procedure was performed as described above for in vitro studies. Western blot analysis: On day 6 after treatment, two tumors per group were excised and frozen in liquid nitrogen. Frozen tumors were homogenized in mortar with pestle and thereafter total proteins were extracted from LoVo tumors using RIPA lysis buffer (Santa Cruz Biotechnology) according to the manufacturer's instructions. The Western blot analysis was performed as described above for in vitro studies. Immunohistochemistry: From each experimental group, tumors were excised at day 6 post-treatment. Tumors were fixed in 10% buffered formalin and embedded in paraffin. Two 5-mm thick sections were cut from each paraffin block. The first section was stained with hematoxylin and eosin and the second was used for immunohistochemical staining. The sections were incubated with polyclonal anti-human K-ras (Proteintech Europe, Chicago, IL) antibody at a 1:100 dilution. A peroxydase-conjugated streptavidin-biotin system was used with diaminobenzidine as the colorogenic reagent, followed by hematoxylin counterstaining. Immunohistochemicaly stained slides were observed under the light microscopy and images were captured by CCD camera (Olympus, Hamburg, Germany). Tumor growth assessment: Antitumor effectiveness of electrogene therapy with pmiRNA-K-ras was assessed by measuring the tumor size twice per week using caliper. Tumor volume was calculated according to the following formula:
, where a, b and c represent perpendicular tumor diameters. Tumor growth was followed until tumors reached a volume of 200 mm 3 . The doubling time (DT) was determined for each individual tumor, and tumor growth delay (GD) was calculated from the mean DT of experimental groups by the following formula: GD ¼DT exp À DT control . Antitumor effect was assessed also on the base of log 10 cell kill calculated from the following formula: log 10 cell kill ¼ GD=3:32ÂDT control , where 3.32 is the number of cell doublings required for a population to increase 1 log 10 unit. 28 Statistical analysis All data were tested for normality of distribution using the Kolmogorov-Smirnov test. Differences between experimental groups were statistically evaluated by oneway analysis of variance followed by the Holm-Sidak test for multiple comparison. A P-value o0.05 was considered to be statistically significant. Sigma Stat statistical software (Systat Software, London, UK) was used for statistical analysis.
Results
In vitro lipofection of colorectal adenocarcinoma cells LoVo and HT29 with siRNA-K-ras molecules reduced K-ras expression and cell survival After lipofection of LoVo and HT29 cells with each of three tested siRNA sequences, levels of mRNA-K-ras were statistically significantly lower in comparison with the group of cells treated with lipofectamine only. The most effective siRNA-K-ras molecule was siRNA-K-ras393, which reduced the level of mRNA-K-ras by 77.2±2.8% in LoVo cells and by 92.6 ± 1.0% in HT29 cells, followed by siRNA-K-ras53 that reduced the level of mRNA-K-ras by 64.4±2.4% in LoVo cells and by 88.3±4.7% in HT29 cells. Control siRNAs reduced mRNA levels by approximately 25% (Figures 1a and d) . These results showed that siRNA-K-ras53 and siRNA-K-ras393 can efficiently inhibit expression of K-ras, therefore they were selected for use in further studies.
To confirm the inhibitory effect of siRNA-K-ras53 and siRNA-K-ras393 on K-ras expression, levels of K-ras proteins were analyzed by western blot analysis. Lipofection of cells with siRNA-K-ras53 or siRNA-K-ras393 reduced the level of K-ras compared with the group of cells treated with lipofectamine only. The effect was more pronounced in LoVo cells, in which siRNA-K-ras393 molecules were more efficient than siRNA-K-ras53. siRNA-K-ras393 reduced the level of K-ras by 74.0% in LoVo cells and by 54.0% in HT29 cells, whereas the level of K-ras in siRNA-K-ras53-treated cells was reduced only by 15.0% in both cell lines. Control siRNAs did not show any effect on levels of K-ras (Figures 1c and e) .
To assess functionality of siRNA-Kras53 or siRNAKras393 introduced into the cells with lipofectamine, clonogenic assay was performed. None of the siRNA molecules significantly reduced the survival of HT29 cells in comparison with cells that were treated with lipofectamine only. In LoVo cells, survival of cells after lipofection with siRNA-K-ras53 decreased by 8.3 ± 3.7%, whereas lipofection with siRNA-K-ras393 decreased cell survival by 27.8±2.3% in comparison with cells that were treated with lipofectamine only. Relative survival of LoVo cells after exposure to siRNA-K-ras393 was statistically significantly lower than that after exposure to control siRNA (Figures 1c and f) . On the basis of these and previous results, we concluded that among the tested siRNA molecules, siRNA-K-ras393 has the greatest therapeutic potential for in vivo application and LoVo cells with K-ras mutation were selected for further experiments.
Construction of plasmid DNA, encoding miRNA-K-ras Several studies have shown that inhibition of target gene expression with siRNA molecules is transient (2-4  days) . 29, 30 For more prolonged silencing effect, the plasmid DNA encoding miRNA (pmiRNA-K-ras) was used in our study. A miRNA-K-ras sequence was designed on the basis of the most efficient siRNA-K-ras sequence. The DNA duplexes corresponding to siRNA-K-ras393 were ligated into pcDNATM6.2-GW/± EmGFP-miR plasmid vector (Invitrogen), which drives the expression of hairpin miRNA-K-ras and green fluorescence protein (GFP) under the control of cytomegalovirus promoter. The plasmid was named pmiRNA-K-ras (Figure 2 ), whereas the control plasmid was named pmiRNA-ctrl.
In vitro electrotransfection of colorectal adenocarcinoma cells LoVo with pmiRNA-K-ras reduced K-ras expression and cell survival The electrotransfection efficiency of LoVo cells with pmiRNA-K-ras was 11.5 ± 2.4% and with pmiRNA-ctrl it was 14.2 ± 7.0% (Figure 3a) . With this transfection efficiency, the level of mRNA-K-ras in LoVo cells after electrotransfection with pmiRNA-K-ras decreased by 28.3 ± 7.4% in comparison with untreated control group. Electroporation alone and electrotransfection with pmiRNA-ctrl minimally reduced the levels of mRNA-K-ras (Figure 3b) . The results of western blot analysis showed 90% lower K-ras protein level after electrotransfection with pmiRNA-K-ras in comparison with untreated control group (Figure 3c ).
To assess the functionality of pmiRNA-K-ras introduced into LoVo cells by EP, a clonogenic assay was performed. LoVo cells showed 42.2 ± 1.3% reduction in cell survival after treatment with electric pulses only in comparison with untreated control group. Electrotransfection of LoVo cells with pmiRNA-K-ras statistically significantly lowered the survival of LoVo cells in comparison with electroporated cells, namely by 35.1 ± 7.3%. Cell survival after electrotransfection with pmiRNA-K-ras was lower even in comparison with the group of cells that were electrotransfected with control plasmid DNA (pmiRNA-ctrl), but the difference was not statistically significant, which may indicate the toxicity of applied plasmid DNA (Figure 3d ). In vivo electrotransfection of LoVo tumors with pmiRNA-K-ras inhibited tumor growth as a consequence of reduced mRNA-K-ras expression and K-ras protein levels Immunohistochemistry showed dark-brown positive reaction on slices of tumors from control groups, whereas the slices of tumors that were electrotransfected with pmiRNA-K-ras showed light-brown reaction with lower intensity (Figure 4a ). These results showed that miRNA-K-ras reduced the K-ras expression in tumors. On the basis of the fact that K-ras silencing induces cell death, the fraction of necrosis was determined by Image J analysis software measuring the area fraction of necrosis on tumor slices. Necrosis occupied the largest area in the group of tumors that was electrotransfected with pmiRNA-K-ras (B60%), whereas in other experimental groups it ranged between 0 and 30% (Figure 4b) . Results of western blot analysis confirmed the results of immunohistochemistry, demonstrating that electrotransfection of LoVo tumors with pmiRNA-K-ras reduced K-ras protein level by 95% in comparison with untreated control group of tumors. In other experimental groups, K-ras protein levels did not decrease by more than 12% (10% in case of EP and 12% in the case of electrotransfection with pmiRNA-ctrl) compared with the untreated control group of tumors (Figure 4c ). Analysis of mRNA-K-ras levels normalized to untreated control tumors showed 76.7 ± 4.3% reduced K-ras expression in tumors electrotransfected with pmiRNA-K-ras, which statistically significantly differed from other treatment groups. Electroporation of LoVo tumors and electrotransfection with pmiRNA-ctrl reduced levels of mRNA-K-ras by 4.5±3.8 and 6.0±9.2%, respectively (Figure 4d) . Analysis of tumor volume measurements showed that untreated tumors and tumors injected with plasmid DNA only (pmiRNA-K-ras or pmiRNA-ctrl) or electroporated only resulted in progressive tumor growth. The doubling times of tumors within these experimental groups were B 8-10 days and did not differ statistically significantly. Tumors electrotransfected with pmiRNA-K-ras showed suppression in tumor growth during the first 6 days after treatment. Thereafter, their growth continued with the same rate as in control groups. Notably, electrotransfection with pmiRNA-K-ras statistically significantly delayed tumor growth compared with tumors treated with injection of pmiRNA-K-ras or EP only. The tumor Figure 2 Schematic diagram of the plasmid DNA encoding miRNA-K-ras (pmiRNA-K-ras). The sequence corresponding to the most efficient small interfering RNA (siRNA) was ligated into the pcDNATM6.2-GW/± EmGFP-miR plasmid vector. This vector contained green fluorescent protein (GFP), which allowed us to detect the cells in which knockdown is occurring, and it contained flanking and loop sequences from an endogenous microRNA (miRNA), which direct the excision of the exogenous miRNA from a cytomegalovirus (CMV) promoter-derived transcript (pre-miRNA) Abbreviations: EmGFP, emerald GFP; P CMV , cytomegalovirus promoter; TK pA , TK polyadenylation signal; f1 ori, f1 origin; SV40 ori, SV40 early promoter and origin; SV40 pA, SV40 polyadenylation signal; pUC ori, pUC origin.
growth after electrotransfection with pmiRNA-K-ras in comparison with tumors electrotransfected with pmiR-NA-ctrl was also delayed. Owing to small number of animals in experimental groups, differences between these two experimental groups were not statistically significant ( Figure 5 ). Furthermore, calculated log values of killed cells in tumors after different treatments normalized to untreated control group of tumors, showed threefold higher number of killed cells after electrotransfection with pmiRNA-K-ras compared with tumors that were only electroporated, and twofold higher number of killed cells compared with tumors electrotransfected with pmiRNActrl ( Table 1) .
Discussion
The results of our study showed that miRNA molecules targeting mutant K-ras by electrotransfer can efficiently silence K-ras expression in colorectal carcinoma cell line (LoVo). Furthermore, inhibition of K-ras expression resulted in efficient reduction of LoVo cell survival in vitro and in solid tumor growth retardation in vivo.
The RNAi technology has many potential therapeutic applications. As not every potential siRNA has an inhibitory effect, the choice of a proper siRNA sequence is crucial for efficient inhibition of K-ras expression. 12, 13 Therefore, to identify the most effective silencing sequence, we tested three different siRNA-K-ras molecules, which resulted in different silencing effect. Differences in the efficacy of gene silencing with siRNA molecules might be associated with secondary structures at targeted position or with a mismatch at certain position, which could dramatically reduce the genesilencing effect. 12, 29, 31 In our case, the siRNA-K-ras393 turned out the most effective as lipofection of colorectal LoVo cells with siRNA-K-ras393 resulted in the highest decrease of K-ras mRNA and protein levels, as well as in the highest reduction of the cell survival. In HT29 cells with WT K-ras, the level of mRNA was significantly reduced, whereas protein expression and cell survival were less affected, demonstrating that although our siRNA sequence did not target the mutation in LoVo cells, the effect of silencing on cell functionality were more pronounced in LoVo cells, which might be due to the reduced level of K-ras protein otherwise abundant in cells harboring mutation. The obtained results are consistent with the results from other in vitro studies performed mostly on pancreatic cell lines (Capan-1, Panc-1, MiaPaca-2 and PC-7), in which therapeutic potential of siRNA/ short hairpin RNA (shRNA) molecules directed against K-ras was also shown. [8] [9] [10] [11] [12] [13] Furthermore, due to a relatively short half-life of synthetic siRNA molecules, 12, 13, 29, 32 we constructed plasmid DNA that encoded a hairpin type of silencing molecules, that is, miRNA molecules with a sequence corresponding to the most efficient siRNA molecule (pmiRNA-K-ras). Most studies dealing with K-ras silencing reported that siRNA or shRNA molecules could specifically inhibit mutant K-ras expression while leaving the WT K-ras unaffected although their sequences differed only in one nucleotide. [8] [9] [10] [11] 13 In our study, siRNA molecules that targeted K-ras mRNA outside the region with mutated codon reduced the levels of mRNA and protein of K-ras in both LoVo cells with mutated K-ras and in HT29 cells harboring WT K-ras. However, our results demonstrated that in HT29 cells, in which their oncogenic potential is due to other mutations, the effect of silencing K-ras did not reflect on cell survival. However, for in vivo experiments, we used EP for local introduction of pmiRNA-K-ras into tumors to fully avoid silencing of the WT K-ras present in normal cells surrounding the tumor. Moreover, EP has proven to be an efficient method for in vitro and in vivo delivery of siRNA/shRNA molecules into tumor cells resulting in successful silencing of reporter or therapeutic genes, including K-ras. Previous in vivo study performed on pancreatic tumors showed that electrotransfection of subcutaneous or orthotopic pancreatic tumors (Panc-1) with synthetic siRNA or plasmid DNA encoding shRNA directed against K-ras dramatically reduced the tumor growth.
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Results obtained from pancreatic tumor model and our results are consistent with the observation that a single electrotransfection of colorectal tumors with pmiRNA-Kras resulted in growth delay of 8 days, whereas in the study by Rejiba et al.
11 the growth delay of 15 days was achieved after two consecutive electrotransfections of pancreatic tumors with pshRNA-K-ras (time interval: 7 days). Our in vivo results showed efficient regression in tumor growth during the first 6 days after electrotransfection with plasmid DNA encoding miRNA directed against K-ras (pmiRNA-K-ras) and, thereafter, the growth rate continued as in control groups. This suggests that electrogene therapy of colorectal tumors with pmiRNA-K-ras was limited by a transient nature of gene silencing. As it has been already proven in previous studies, this limitation might be overcome by repeated administration of silencing molecules. 11, [36] [37] [38] The repetitive treatments might be important for the eradication of tumor cells that fail to be transfected in a single treatment. For repetitive therapies, it is important that gene delivery method is safe and that it can be applied locally, which are both undoubtedly the advantages of EP. 39 This was also confirmed in our study in which the growth of tumors was followed until tumors reached the size of about 200 mm 3 . During this time, no side effects were observed on experimental animals, which also indicated that electrogene therapy with pmiRNA-K-ras can be locally applied in the treatment of tumors.
Despite the finding that K-ras silencing with miRNA did not completely prevent tumor growth, the therapeutic effect of such treatment is obvious, as the fraction of killed cells in tumors electrotransfected with pmiRNA-Kras was twofold greater than in tumors electrotransfected with control pmiRNA-ctrl. Silencing of K-ras expression in LoVo tumors after electrotransfection with pmiRNA-K-ras was confirmed also with quantitative RT-PCR, western blot analysis and immunohistochemistry, which demonstrated reduced K-ras mRNA and protein levels. The reduction in K-ras mRNA level was much greater in tumors than in cells that were electrotransfected with pmiRNA-K-ras in our in vitro experiment. This discrepancy between in vitro and in vivo results may be explained by different sampling times, however, to fully confirm this speculation, a time kinetic study should be performed. In the experiment in vitro, the mRNA was examined the second day after electrotransfection of cells with pmiRNA-K-ras, whereas in the experiment in vivo, the mRNA was examined on the sixth day after electrotransfection of tumors with pmiRNA-K-ras. Results of previous in vitro and in vivo studies targeting reporter gene GFP with siRNA/shRNA showed that the highest gene silencing is obtained between the second and the fifth day after electrotransfection. [33] [34] [35] In our in vitro and in vivo experiments, it was demonstrated that not only the miRNA-K-ras contributed to the reduction in cell and tumor growth, but also the apparent toxicity of plasmid DNA. This was observed from the reduced cell survival and from growth of tumors after electrotransfection with control plasmid DNA (pmiRNA-ctrl). Previous studies proposed that the reduction of growth after treatment with plasmid DNA non-coding for therapeutic protein is due to the activation of immune response of the organism. 40 However, results of our study demonstrate that the inhibition of tumor growth after electrotransfection with pmiRNA-ctrl could not be attributed only to immune response, as tumors were grown in severe combined immunodeficiency mice that have suppressed immune response. Abbreviations: DT, doubling time; GD, growth delay; EP, electroporation. DT, GD and log 10 cell kill values of subcutaneous LoVo tumors exposed to different treatments: intratumoral injection of plasmid DNA encoding miRNA-K-ras (pmiRNA-K-ras) or miRNA-ctrl (pmiRNA-ctrl), EP of tumors, electrotransfection of tumors with pmiRNA-K-ras or with pmiRNA-ctrl. Data are represented as arithmetic mean ± s.e. pooled from seven animals per experimental group (n).
In conclusion, our and previous studies showed that K-ras silencing could be used therapeutically in treatment of different cancers. Our study is, to the best of our knowledge, the first study showing the potential of miRNA molecules for local electrogene treatment of colorectal adenocarcinoma tumors. Further studies in this area may continue using plasmid DNA encoding different siRNA or miRNA molecules for multiple targeting or in combination with other standard treatment modalities for colorectal cancer, which might improve the treatment outcome.
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